Stewart M Bond1,2, Mary S Dietrich3,4, Jill Gilbert5, E Wesley Ely5,6, James C Jackson5, Barbara A Murphy5. 1. Vanderbilt University School of Nursing, Nashville, TN, USA. stewart.bond@bc.edu. 2. Boston College William F. Connell School of Nursing, 378C Maloney Hall, 140 Commonwealth Avenue, Chestnut Hill, MA, 02467, USA. stewart.bond@bc.edu. 3. Vanderbilt University School of Nursing, Nashville, TN, USA. 4. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA. 5. Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. 6. VA TN Valley Geriatric Research Education Clinical Center (GRECC), Department of Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN, USA.
Abstract
PURPOSE: Cancer and cancer therapy-related neurocognitive changes negatively affect quality of life, yet few studies have examined neurocognitive changes in patients with head and neck cancer. The purpose of this study was to evaluate neurocognitive performance in patients with head and neck cancer at baseline before starting treatment and 3 months after treatment completion to assess treatment-associated changes in performance. METHODS: Patients with head and neck cancer who were to receive primary or adjuvant chemoradiation (N = 55) underwent neuropsychological testing before and 3 months posttreatment. Changes in neurocognitive performance were assessed using a practice effect adjusted Reliable Change Index. RESULTS: At baseline, 38 % of patients exhibited global neurocognitive impairment. Posttreatment, 21.8 % demonstrated declines in neurocognitive performance in at least one domain. Declines in domain-specific performance ranged from 1.8 to 12.7 % with the greatest decline in language, specifically verb retrieval. Domain-specific improvements ranged from 0 to 7.3 %. CONCLUSIONS: Patients had a high prevalence of baseline neurocognitive impairment. While neurocognitive performance posttreatment remained unchanged in the majority, almost 13 % suffered declines in language. Small percentages of patients exhibited improvements in their performance. Long-term effects and risk factors for neurocognitive decline in this population should be studied on a larger scale.
PURPOSE:Cancer and cancer therapy-related neurocognitive changes negatively affect quality of life, yet few studies have examined neurocognitive changes in patients with head and neck cancer. The purpose of this study was to evaluate neurocognitive performance in patients with head and neck cancer at baseline before starting treatment and 3 months after treatment completion to assess treatment-associated changes in performance. METHODS:Patients with head and neck cancer who were to receive primary or adjuvant chemoradiation (N = 55) underwent neuropsychological testing before and 3 months posttreatment. Changes in neurocognitive performance were assessed using a practice effect adjusted Reliable Change Index. RESULTS: At baseline, 38 % of patients exhibited global neurocognitive impairment. Posttreatment, 21.8 % demonstrated declines in neurocognitive performance in at least one domain. Declines in domain-specific performance ranged from 1.8 to 12.7 % with the greatest decline in language, specifically verb retrieval. Domain-specific improvements ranged from 0 to 7.3 %. CONCLUSIONS:Patients had a high prevalence of baseline neurocognitive impairment. While neurocognitive performance posttreatment remained unchanged in the majority, almost 13 % suffered declines in language. Small percentages of patients exhibited improvements in their performance. Long-term effects and risk factors for neurocognitive decline in this population should be studied on a larger scale.
Entities:
Keywords:
Cognitive function; Head and neck cancer; Neurocognitive performance; Supportive care; Symptom management
Authors: Raul Gonzalez; Robert K Heaton; David J Moore; Scott Letendre; Ronald J Ellis; Tanya Wolfson; Thomas Marcotte; Mariana Cherner; Julie Rippeth; Igor Grant Journal: J Int Neuropsychol Soc Date: 2003-01 Impact factor: 2.892
Authors: Sara Gandini; Edoardo Botteri; Simona Iodice; Mathieu Boniol; Albert B Lowenfels; Patrick Maisonneuve; Peter Boyle Journal: Int J Cancer Date: 2008-01-01 Impact factor: 7.396
Authors: Ronald Maggiore; Zachary S Zumsteg; Karlynn BrintzenhofeSzoc; Kelly M Trevino; Ajeet Gajra; Beatriz Korc-Grodzicki; Joel B Epstein; Stewart M Bond; Ira Parker; Julie A Kish; Barbara A Murphy; Noam A VanderWalde Journal: Int J Radiat Oncol Biol Phys Date: 2017-07-15 Impact factor: 7.038
Authors: Moira A Visovatti; Mi Sook Jung; Heidi Mason; Mary Beth DeRubeis; Francis P Worden; Debra L Barton Journal: Cancer Nurs Date: 2022-01-12 Impact factor: 2.760
Authors: Alona Zer; Gregory R Pond; Albiruni R Abdul Razak; Kattleya Tirona; Hui K Gan; Eric X Chen; Brian O'Sullivan; John Waldron; David P Goldstein; Ilan Weinreb; Andrew J Hope; John J Kim; Kelvin K W Chan; Andrew K Chan; Lillian L Siu; Lori J Bernstein Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-01-01 Impact factor: 6.223
Authors: Vitória Piai; Femke Jansen; Kristoffer Dahlslätt; Irma M Verdonck-de Leeuw; Judith Prins; René Leemans; Chris H J Terhaard; Johannes A Langendijk; Robert J Baatenburg de Jong; Johannes H Smit; Robert Takes; Roy P C Kessels Journal: Head Neck Date: 2021-11-19 Impact factor: 3.821
Authors: Judith T Pruijssen; Ashwin Wenmakers; Roy P C Kessels; Vitoria Piai; Frederick J A Meijer; Sjoert A H Pegge; Jacqueline J Loonen; Anil M Tuladhar; Hendrik H G Hansen; Johannes H A M Kaanders; Joyce Wilbers Journal: BMC Cancer Date: 2022-03-05 Impact factor: 4.430
Authors: Seung Won Seol; Brian H Lee; Timothy L Sita; Jay Ram Devineni; Tim J Kruser; Sean Sachdev; Michelle Gentile; Irene Helenowski; Bharat B Mittal Journal: Phys Imaging Radiat Oncol Date: 2022-09-24